Protective effects of Saccharomyces boulardii CNCM I-745 in an experimental model of NSAID-induced enteropathy
äºBeneficial MicrobesSearch for other papers by E. Simon OâBrien in
Current site
Google Scholar
Search for other papers by A. Robert in
Current site
Google Scholar
Search for other papers by D. Gauthier in
Current site
Google Scholar
Search for other papers by A. Le Cavorzin in
Current site
Google Scholar
Search for other papers by J. Planchais in
Current site
Google Scholar
Search for other papers by X. Roux in
Current site
Google Scholar
Search for other papers by M. Verleye in
Current site
Google Scholar
Search for other papers by V. CastagneÌ in
Current site
Google Scholar
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) induce a broad spectrum of gastro-intestinal adverse effects, including ulceration and bleeding. The pathophysiology of NSAID enteropathy is complex and incompletely understood, but some evidence showed that NSAIDs impair the intestinal barrier and cause a gut dysbiosis. Identifying new treatments aiming to reverse or attenuate NSAID-induced adverse effects would have a significant impact on a high number of patients. The aim of this work is to assess the effects of the probiotic yeast Saccharomyces boulardii CNCM I-745 (Sb) on a model of NSAID-induced enteropathy. Four groups of mice were tested: Control, Indomethacin, Sb, and Sb + Indomethacin. A clinical score was evaluated throughout the experiment. Faecal calprotectin, microbiota and haemoglobin analyses were performed. At the end of the treatments, the small intestine, colon, and caecum lengths, and intestinal permeability were measured. Sections of ileum and jejunum were observed to assess a histological score and ileal cytokines were measured by immunoassay. Indomethacin-treated animals showed an increase in their clinical scores, reflecting a worsening of their general state. Mice co-treated with Sb and indomethacin displayed an improvement of their clinical score in comparison with mice treated with indomethacin alone. Sb prevented the indomethacin-induced shortening of the small intestine and caecum, and significantly attenuated the severity of intestinal lesions. Sb also prevented the increase in faecal calprotectin, reduced faecal haemoglobin, and prevented the increase of intestinal permeability in mice treated with indomethacin. Sb also counteracted the increase of faecal bacteria associated with the pathogenesis of NSAID-enteropathy. In conclusion, our results show a protective effect of Sb in a model of indomethacin-induced enteropathy. Sb improved the intestinal barrier function and exerted a positive action on gut microbiota composition.
-
Abbas, Z., Yakoob, J., Jafri, W., Ahmad, Z., Azam, Z., Usman, M.W., Shamim, S. and Islam, M., 2014. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. European Journal of Gastroenterology and Hepatology 26: 630-639. https://doi.org/10.1097/MEG.0000000000000094
-
Abraham, N.S. and Graham, D.Y., 2005. NSAIDs and gastrointestinal complications: new clinical challenges. Expert Opinion on Pharmacotherapy 6: 2681-2689. https://doi.org/10.1517/14656566.6.15.2681
-
Ansorge, R., Birolo, G., James, S.A. and Telatin, A., 2021. Dadaist2: a toolkit to automate and simplify statistical analysis and plotting of metabarcoding experiments. International Journal of Molecular Sciences 22: 5309. https://doi.org/10.3390/ijms22105309
-
Barc, M.-C., Charrin-Sarnel, C., Rochet, V., Bourlioux, F., SandreÌ, C., Boureau, H., DoreÌ, J. and Collignon, A., 2008. Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: influence of Saccharomyces boulardii. Anaerobe 14: 229-233. https://doi.org/10.1016/j.anaerobe.2008.04.003
-
Bjarnason, I., Scarpignato, C., Holmgren, E., Olszewski, M., Rainsford, K.D. and Lanas, A., 2018. Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology 154: 500-514. https://doi.org/10.1053/j.gastro.2017.10.049
-
Blackler, R.W., Palma, G. de, Manko, A., Da Silva, G.J., Flannigan, K.L., Bercik, P., Surette, M.G., Buret, A.G. and Wallace, J.L., 2015. Deciphering the pathogenesis of NSAID enteropathy using proton pump inhibitors and a hydrogen sulfide-releasing NSAID. American Journal of Physiology â Gastrointestinal and Liver Physiology 308: G994-G1003. https://doi.org/10.1152/ajpgi.00066.2015
-
BrandaÌo, R.L., Castro, I.M., Bambirra, E.A., Amaral, S.C., Fietto, L.G., Tropia, M.J., Neves, M.J., Dos Santos, R.G., Gomes, N.C. and Nicoli, J.R., 1998. Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae. Applied and Environmental Microbiology 64: 564-568. https://doi.org/10.1128/AEM.64.2.564-568.1998
-
Brun, P., Scarpa, M., Marchiori, C., Sarasin, G., Caputi, V., Porzionato, A., Giron, M.C., PaluÌ, G. and Castagliuolo, I., 2017. Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS. PLoS one 12: e0181863. https://doi.org/10.1371/journal.pone.0181863
-
Buccigrossi, V., Laudiero, G., Russo, C., Miele, E., Sofia, M., Monini, M., Ruggeri, F.M. and Guarino, A., 2014. Chloride secretion induced by rotavirus is oxidative stress-dependent and inhibited by Saccharomyces boulardii in human enterocytes. PLoS one 9: e99830. https://doi.org/10.1371/journal.pone.0099830
-
Buts, J.-P. and Keyser, N. de, 2006. Effects of Saccharomyces boulardii on intestinal mucosa. Digestive Diseases and Sciences 51: 1485-1492. https://doi.org/10.1007/s10620-005-9016-x
-
Cani, P.D., Depommier, C., Derrien, M., Everard, A. and De Vos, W.M., 2022. Author Correction: Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms. Nature Reviews Gastroenterology and Hepatology 19: 682. https://doi.org/10.1038/s41575-022-00650-6
-
Castagliuolo, I., LaMont, J.T., Nikulasson, S.T. and Pothoulakis, C., 1996. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infection and immunity 64, 5225-5232. https://doi.org/10.1128/iai.64.12.5225-5232.1996
-
Chen, C.-Y., Kao, C.-L. and Liu, C.-M., 2018. The cancer prevention, anti-inflammatory and anti-oxidation of bioactive phytochemicals targeting the TLR4 signaling pathway. International Journal of Molecular Sciences 19: 2729. https://doi.org/10.3390/ijms19092729
-
Choi, C.H., Jo, S.Y., Park, H.J., Chang, S.K., Byeon, J.-S. and Myung, S.-J., 2011. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. Journal of Clinical Gastroenterology 45: 679-683. https://doi.org/10.1097/MCG.0b013e318204593e
-
Collignon, A., SandreÌ, C. and Barc, M.C., 2010. Saccharomyces boulardii module les proprieÌteÌs descellules dendritiques et le deÌseÌquilibre du microbioteintestinal apreÌs un traitement antibiotique [Saccharomyces boulardii modulates dendritic cell properties and intestinal microbiota disruption after antibiotic treatment]. GastroenteÌrologie Clinique et Biologique 34 Suppl 1: S71-S78. https://doi.org/10.1016/S0399-8320(10)70024-5. PMID: 20889009
-
Czerucka, D. and Rampal, P., 2019. Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections. World Journal of Gastroenterology 25: 2188-2203. https://doi.org/10.3748/wjg.v25.i18.2188
-
Dinleyici, E.C., Kara, A., Ozen, M. and Vandenplas, Y., 2014. Saccharomyces boulardii CNCM I-745 in different clinical conditions. Expert Opinion on Biological Therapy 14: 1593-1609. https://doi.org/10.1517/14712598.2014.937419
-
Endo, H., Higurashi, T., Hosono, K., Sakai, E., Sekino, Y., Iida, H., Sakamoto, Y., Koide, T., Takahashi, H., Yoneda, M., Tokoro, C., Inamori, M., Abe, Y. and Nakajima, A., 2011. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. Journal of Gastroenterology 46: 894-905. https://doi.org/10.1007/s00535-011-0410-1
-
Feizizadeh, S., Salehi-Abargouei, A. and Akbari, V., 2014. Efficacy and safety of Saccharomyces boulardii for acute diarrhea. Pediatrics 134: e176-91. https://doi.org/10.1542/peds.2013-3950
-
Fornai, M., Antonioli, L., Pellegrini, C., Colucci, R., Sacco, D., Tirotta, E., Natale, G., Bartalucci, A., Flaibani, M., Renzulli, C., Ghelardi, E., Blandizzi, C. and Scarpignato, C., 2016. Small bowel protection against NSAID-injury in rats: effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. Pharmacological Research 104: 186-196. https://doi.org/10.1016/j.phrs.2015.12.031
-
Fornai, M., Pellegrini, C., Benvenuti, L., Tirotta, E., Gentile, D., Natale, G., Ryskalin, L., Colucci, R., Piccoli, E., Ghelardi, E., Blandizzi, C. and Antonioli, L., 2020. Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy. Nutrition 70: 110583. https://doi.org/10.1016/j.nut.2019.110583
-
Horibe, S., Tanahashi, T., Kawauchi, S., Mizuno, S. and Rikitake, Y., 2016. Preventative effects of sodium alginate on indomethacininduced small-intestinal injury in mice. International Journal of Medical Sciences 13: 653-663. https://doi.org/10.7150/ijms.16232
-
Jacob, M., Foster, R., Sigthorsson, G., Simpson, R. and Bjarnason, I., 2007. Role of bile in pathogenesis of indomethacin-induced enteropathy. Archives of Toxicology 81: 291-298. https://doi.org/10.1007/s00204-006-0149-2
-
Jawhara, S. and Poulain, D., 2007. Saccharomyces boulardii decreases inflammation and intestinal colonization by Candida albicans in a mouse model of chemically-induced colitis. Medical Mycology 45: 691-700. https://doi.org/10.1080/13693780701523013
-
Kabbani, T.A., Pallav, K., Dowd, S.E., Villafuerte-Galvez, J., Vanga, R.R., Castillo, N.E., Hansen, J., Dennis, M., Leffler, D.A. and Kelly, C.P., 2017. Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers. Gut Microbes 8: 17-32. https://doi.org/10.1080/19490976.2016.1267890
-
Kelesidis, T. and Pothoulakis, C., 2012. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therapeutic Advances in Gastroenterology 5: 111-125. https://doi.org/10.1177/1756283X11428502
-
Kinouchi, T., Kataoka, K., Bing, S.R., Nakayama, H., Uejima, M., Shimono, K., Kuwahara, T., Akimoto, S., Hiraoka, I. and Ohnishi, Y., 1998. Culture supernatants of Lactobacillus acidophilus and Bifidobacterium adolescentis repress ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug by suppressing unbalanced growth of aerobic bacteria and lipid peroxidation. Microbiology and Immunology 42: 347-355. https://doi.org/10.1111/j.1348-0421.1998.tb02294.x
-
Klindworth, A., Pruesse, E., Schweer, T., Peplies, J., Quast, C., Horn, M. and Glöckner, F.O., 2013. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencingbased diversity studies. Nucleic Acids Research 41: e1. https://doi.org/10.1093/nar/gks808
-
Koga, H., Aoyagi, K., Matsumoto, T., Iida, M. and and Fujishima, M., 1999. Experimental enteropathy in athymic and euthymic rats: synergistic role of lipopolysaccharide and indomethacin. American Journal of Physiology â Gastrointestinal and Liver Physiology 276: G576-G582.
-
Lanas, A. and SopenÌa, F., 2009. Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications. Gastroenterology Clinics of North America 38: 333-352. https://doi.org/10.1016/j.gtc.2009.03.007
-
Li, M., Zhu, L., Xie, A. and Yuan, J., 2015. Oral administration of Saccharomyces boulardii ameliorates carbon tetrachloride-induced liver fibrosis in rats via reducing intestinal permeability and modulating gut microbial composition. Inflammation 38, 170- 179. https://doi.org/10.1007/s10753-014-0019-7
-
Maseda, D. and Ricciotti, E., 2020. NSAID-Gut microbiota interactions. Frontiers in Pharmacology 11: 1153. https://doi.org/10.3389/fphar.2020.01153
-
Maseda, D., Zackular, J.P., Trindade, B., Kirk, L., Roxas, J.L., Rogers, L.M., Washington, M.K., Du, L., Koyama, T., Viswanathan, V.K., Vedantam, G., Schloss, P.D., Crofford, L.J., Skaar, E.P. and Aronoff, D.M., 2019. Nonsteroidal anti-inflammatory drugs alter the microbiota and exacerbate Clostridium difficile colitis while dysregulating the inflammatory response. mBio 10: e02282-18. https://doi.org/10.1128/mBio.02282-18
-
McFarland, L.V., Surawicz, C.M., Greenberg, R.N., Fekety, R., Elmer, G.W., Moyer, K.A., Melcher, S.A., Bowen, K.E., Cox, J.L. and Noorani, Z., 1994. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271: 1913-1918
-
Montalto, M., Gallo, A., Curigliano, V., DâOnofrio, F., Santoro, L., Covino, M., Dalvai, S., Gasbarrini, A. and Gasbarrini, G., 2010. Clinical trial: The effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy â a randomized, double-blind, cross-over, placebo-controlled study. Alimentary Pharmacology and Therapeutics 32: 209-214. https://doi.org/10.1111/j.1365-2036.2010.04324.x
-
Montalto, M., Gallo, A., Gasbarrini, A. and Landolfi, R., 2013. NSAID enteropathy: could probiotics prevent it? Journal of Gastroenterology 48: 689-697. https://doi.org/10.1007/s00535-012-0648-2
-
MoreÌ, M.I. and Swidsinski, A., 2015. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis â a review. Clinical and Experimental Gastroenterology 8: 237-255. https://doi.org/10.2147/CEG.S85574
-
Mumy, K.L., Chen, X., Kelly, C.P. and McCormick, B.A., 2008. Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events. American Journal of Physiology â Gastrointestinal and Liver Physiology 294: G599-609. https://doi.org/10.1152/ajpgi.00391.2007
-
Nadatani, Y., Watanabe, T., Tanigawa, T., Machida, H., Okazaki, H., Yamagami, H., Watanabe, K., Tominaga, K., Fujiwara, Y. and Arakawa, T., 2012. High mobility group box 1 promotes small intestinal damage induced by nonsteroidal anti-inflammatory drugs through Toll-like receptor 4. American Journal of Pathology 181: 98-110. https://doi.org/10.1016/j.ajpath.2012.03.039
-
OcoÌn, B., Anzola, A., Ortega-GonzaÌlez, M., Zarzuelo, A., SuaÌrez, M.D., SaÌnchez de Medina, F. and MartıÌnez-Augustin, O., 2013. Active hexose-correlated compound and Bifidobacterium longum BB536 exert symbiotic effects in experimental colitis. European Journal of Nutrition 52: 457-466. https://doi.org/10.1007/s00394-012-0347-z
-
R Core Team, 2018. R: a language and environment for statistical computing: R Foundation for Statistical Computing, Vienna, Austria.
-
Rath, H.C., Schultz, M., Freitag, R., Dieleman, L.A., Li, F., Linde, H.J., Schölmerich, J. and Sartor, R.B., 2001. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infection and Immunity 69: 2277-2285. https://doi.org/10.1128/IAI.69.4.2277-2285.2001
-
Reuter, B.K., Davies, N.M. and Wallace, J.L., 1997. Nonsteroidal antiinflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 112: 109-117. https://doi.org/10.1016/s0016-5085(97)70225-7
-
Robert, A. and Asano, T., 1977. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins 14: 333-341. https://doi.org/10.1016/0090-6980(77)90178-2
-
Rodrigues, V.F., Elias-Oliveira, J., Pereira, IÌ.S., Pereira, J.A., Barbosa, S.C., Machado, M.S.G. and Carlos, D., 2022. Akkermansia muciniphila and gut immune system: a good friendship that attenuates inflammatory bowel disease, obesity, and diabetes. Frontiers in Immunology 13: 934695. https://doi.org/10.3389/fimmu.2022.934695
-
RodrıÌguez-Nogales, A., Algieri, F., Garrido-Mesa, J., Vezza, T., Utrilla, M.P., Chueca, N., GarcıÌa, F., RodrıÌguez-Cabezas, M.E. and GaÌlvez, J., 2018. Intestinal anti-inflammatory effect of the probiotic Saccharomyces boulardii in DSS-induced colitis in mice: Impact on microRNAs expression and gut microbiota composition. Journal of Nutritional Biochemistry 61: 129-139. https://doi.org/10.1016/j.jnutbio.2018.08.005
-
Rogers, M.A.M. and Aronoff, D.M., 2016. The influence of nonsteroidal anti-inflammatory drugs on the gut microbiome. Clinical Microbiology and Infection 22: 178.e1-178.e9. https://doi.org/10.1016/j.cmi.2015.10.003
-
Sougioultzis, S., Simeonidis, S., Bhaskar, K.R., Chen, X., Anton, P.M., Keates, S., Pothoulakis, C. and Kelly, C.P., 2006. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochemical and Biophysical Research Communications 343: 69-76. https://doi.org/10.1016/j.bbrc.2006.02.080
-
Soyturk, M., Saygili, S.M., Baskin, H., Sagol, O., Yilmaz, O., Saygili, F. and Akpinar, H., 2012. Effectiveness of Saccharomyces boulardii in a rat model of colitis. World Journal of Gastroenterology 18: 6452-60; discussion 6459. https://doi.org/10.3748/wjg.v18.i44.6452
-
Tanigawa, T., Watanabe, T., Otani, K., Nadatani, Y., Ohkawa, F., Sogawa, M., Yamagami, H., Shiba, M., Watanabe, K., Tominaga, K., Fujiwara, Y., Takeuchi, K. and Arakawa, T., 2013. Rebamipide inhibits indomethacin-induced small intestinal injury: possible involvement of intestinal microbiota modulation by upregulation of ?-defensin 5. European Journal of Pharmacology 704: 64-69. https://doi.org/10.1016/j.ejphar.2013.02.010
-
TeraÌn-Ventura, E., Aguilera, M., Vergara, P. and MartıÌnez, V., 2014. Specific changes of gut commensal microbiota and TLRs during indomethacin-induced acute intestinal inflammation in rats. Journal of Crohnâs and Colitis 8: 1043-1054. https://doi.org/10.1016/j.crohns.2014.02.001
-
Terciolo, C., Dapoigny, M. and Andre, F., 2019. Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption. Clinical and Experimental Gastroenterology 12: 67-82. https://doi.org/10.2147/CEG.S181590
-
Terciolo, C., Dobric, A., Ouaissi, M., Siret, C., Breuzard, G., Silvy, F., Marchiori, B., Germain, S., Bonier, R., Hama, A., Owens, R., Lombardo, D., Rigot, V. and AndreÌ, F., 2017. Saccharomyces boulardii CNCM I-745 restores intestinal barrier integrity by regulation of e-cadherin recycling. Journal of Crohnâs and Colitis 11: 999-1010. https://doi.org/10.1093/ecco-jcc/jjx030
-
Thomas, S., Przesdzing, I., Metzke, D., Schmitz, J., Radbruch, A. and Baumgart, D.C., 2009. Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation. Clinical and Experimental Immunology 156: 78-87. https://doi.org/10.1111/j.1365-2249.2009.03878.x
-
Uejima, M., Kinouchi, T., Kataoka, K., Hiraoka, I. and Ohnishi, Y., 1996. Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug. Microbiology and Immunology 40: 553-560. https://doi.org/10.1111/j.1348-0421.1996.tb01108.x
-
Underwood, M.A., Arriola, J., Gerber, C.W., Kaveti, A., Kalanetra, K.M., Kananurak, A., Bevins, C.L., Mills, D.A. and Dvorak, B., 2014. Bifidobacterium longum subsp. infantis in experimental necrotizing enterocolitis: alterations in inflammation, innate immune response, and the microbiota. Pediatric Research 76: 326-333. https://doi.org/10.1038/pr.2014.102
-
Wallace, J.L., 2013. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World Journal of Gastroenterology 19: 1861-1876. https://doi.org/10.3748/wjg.v19.i12.1861
-
Wallace, J.L., Syer, S., Denou, E., Palma, G. de, Vong, L., McKnight, W., Jury, J., Bolla, M., Bercik, P., Collins, S.M., Verdu, E. and Ongini, E., 2011. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 141: 1314-1322, 1322.e1-5. https://doi.org/10.1053/j.gastro.2011.06.075
-
Wang, B., Hussain, A., Zhou, Y., Zeng, Z., Wang, Q., Zou, P., Gong, L., Zhao, P. and Li, W., 2020. Saccharomyces boulardii attenuates inflammatory response induced by Clostridium perfringens via TLR4/TLR15-MyD8 pathway in HD11 avian macrophages. Poultry Science 99: 5356-5365. https://doi.org/10.1016/j.psj.2020.07.045
-
Wang, X., Tang, Q., Hou, H., Zhang, W., Li, M., Chen, D., Gu, Y., Wang, B., Hou, J., Liu, Y. and Cao, H., 2021. Gut microbiota in NSAID enteropathy: new insights from inside. Frontiers in Cellular and Infection Microbiology 11: 679396. https://doi.org/10.3389/ fcimb.2021.679396
-
Watanabe, T., Higuchi, K., Kobata, A., Nishio, H., Tanigawa, T., Shiba, M., Tominaga, K., Fujiwara, Y., Oshitani, N., Asahara, T., Nomoto, K., Takeuchi, K. and Arakawa, T., 2008. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 57: 181-187. https://doi.org/10.1136/gut.2007.125963
-
Watanabe, T., Nishio, H., Tanigawa, T., Yamagami, H., Okazaki, H., Watanabe, K., Tominaga, K., Fujiwara, Y., Oshitani, N., Asahara, T., Nomoto, K., Higuchi, K., Takeuchi, K. and Arakawa, T., 2009. Probiotic Lactobacillus casei strain Shirota prevents indomethacininduced small intestinal injury: involvement of lactic acid. American Journal of Physiology. Gastrointestinal and Liver physiology 297: G506-G513. https://doi.org/10.1152/ajpgi.90553.2008
-
Whitfield-Cargile, C.M., Cohen, N.D., Chapkin, R.S., Weeks, B.R., Davidson, L.A., Goldsby, J.S., Hunt, C.L., Steinmeyer, S.H., Menon, R., Suchodolski, J.S., Jayaraman, A. and Alaniz, R.C., 2016. The microbiota-derived metabolite indole decreases mucosal inflammation and injury in a murine model of NSAID enteropathy. Gut Microbes 7: 246-261. https://doi.org/10.1080/19490976.2016.1156827
-
Xiao, X., Nakatsu, G., Jin, Y., Wong, S., Yu, J. and Lau, J.Y.W., 2017. Gut microbiota mediates protection against enteropathy induced by indomethacin. Scientific Reports 7: 40317. https://doi.org/10.1038/srep40317
| å ¨é¨æé´ | è¿å»ä¸å¹´ | è¿å»30天 | |
|---|---|---|---|
| æè¦æµè§æ¬¡æ° | 0 | 0 | 0 |
| å ¨ææµè§æ¬¡æ° | 609 | 155 | 14 |
| PDFä¸è½½æ¬¡æ° | 780 | 215 | 16 |
Protective effects of Saccharomyces boulardii CNCM I-745 in an experimental model of NSAID-induced enteropathy
äºBeneficial MicrobesSearch for other papers by E. Simon OâBrien in
Current site
Google Scholar
PubMed
Search for other papers by A. Robert in
Current site
Google Scholar
PubMed
Search for other papers by D. Gauthier in
Current site
Google Scholar
PubMed
Search for other papers by A. Le Cavorzin in
Current site
Google Scholar
PubMed
Search for other papers by J. Planchais in
Current site
Google Scholar
PubMed
Search for other papers by X. Roux in
Current site
Google Scholar
PubMed
Search for other papers by M. Verleye in
Current site
Google Scholar
PubMed
Search for other papers by V. CastagneÌ in
Current site
Google Scholar
PubMed
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) induce a broad spectrum of gastro-intestinal adverse effects, including ulceration and bleeding. The pathophysiology of NSAID enteropathy is complex and incompletely understood, but some evidence showed that NSAIDs impair the intestinal barrier and cause a gut dysbiosis. Identifying new treatments aiming to reverse or attenuate NSAID-induced adverse effects would have a significant impact on a high number of patients. The aim of this work is to assess the effects of the probiotic yeast Saccharomyces boulardii CNCM I-745 (Sb) on a model of NSAID-induced enteropathy. Four groups of mice were tested: Control, Indomethacin, Sb, and Sb + Indomethacin. A clinical score was evaluated throughout the experiment. Faecal calprotectin, microbiota and haemoglobin analyses were performed. At the end of the treatments, the small intestine, colon, and caecum lengths, and intestinal permeability were measured. Sections of ileum and jejunum were observed to assess a histological score and ileal cytokines were measured by immunoassay. Indomethacin-treated animals showed an increase in their clinical scores, reflecting a worsening of their general state. Mice co-treated with Sb and indomethacin displayed an improvement of their clinical score in comparison with mice treated with indomethacin alone. Sb prevented the indomethacin-induced shortening of the small intestine and caecum, and significantly attenuated the severity of intestinal lesions. Sb also prevented the increase in faecal calprotectin, reduced faecal haemoglobin, and prevented the increase of intestinal permeability in mice treated with indomethacin. Sb also counteracted the increase of faecal bacteria associated with the pathogenesis of NSAID-enteropathy. In conclusion, our results show a protective effect of Sb in a model of indomethacin-induced enteropathy. Sb improved the intestinal barrier function and exerted a positive action on gut microbiota composition.
| å ¨é¨æé´ | è¿å»ä¸å¹´ | è¿å»30天 | |
|---|---|---|---|
| æè¦æµè§æ¬¡æ° | 0 | 0 | 0 |
| å ¨ææµè§æ¬¡æ° | 609 | 155 | 14 |
| PDFä¸è½½æ¬¡æ° | 780 | 215 | 16 |
